What is the TNM staging system for primary sigmoid colon adenocarcinoma, including T, N, M categories and stage groupings?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

TNM Staging System for Sigmoid Colon Adenocarcinoma

The sigmoid colon is staged using the UICC TNM classification system (8th edition, 2017), which is identical to the staging system for all colon cancers, with T stage based on depth of invasion, N stage on number of involved regional lymph nodes, and M stage on presence of distant metastases. 1

T Stage (Primary Tumor Depth of Invasion)

The T classification describes how deeply the tumor has invaded through the bowel wall layers 1:

  • Tis: Carcinoma in situ—cancer cells confined within the mucosal lamina propria (intramucosal) with no extension through the muscularis mucosae into the submucosa 1
  • T1: Tumor invades submucosa 1
  • T2: Tumor invades muscularis propria 1
  • T3: Tumor invades through the muscularis propria into the subserosa or into non-peritonealized pericolic tissues 1
  • T4a: Tumor perforates the visceral peritoneum 1
  • T4b: Tumor directly invades other organs or structures 1

Important caveat: Unlike rectal cancer, sigmoid colon tumors do not require T3 sub-classification by depth of extramural invasion, as this distinction is primarily relevant for rectal cancer treatment planning. 2

N Stage (Regional Lymph Node Involvement)

The N classification is based on the number of involved regional lymph nodes, not their size or location 1:

  • N0: No regional lymph node metastasis 1
  • N1a: Metastasis in 1 regional lymph node 1
  • N1b: Metastasis in 2-3 regional lymph nodes 1
  • N1c: Tumor deposits (satellites) in the subserosa or non-peritonealized pericolic soft tissue without regional lymph node metastasis 1
  • N2a: Metastasis in 4-6 regional lymph nodes 1
  • N2b: Metastasis in 7 or more regional lymph nodes 1

Critical pitfall: N1c should only be used when there are tumor deposits but no positive lymph nodes; if any lymph nodes are positive, stage according to the number of positive nodes and document deposits separately. 1, 3

M Stage (Distant Metastasis)

The M classification describes the presence and extent of distant metastatic disease 1:

  • M0: No distant metastasis 1
  • M1a: Metastasis confined to one organ (liver, lung, ovary, non-regional lymph nodes) without peritoneal metastases 1
  • M1b: Metastasis in more than one organ 1
  • M1c: Metastasis to the peritoneum with or without other organ involvement 1

Stage Groupings

The TNM categories are combined into overall stages that guide treatment and predict prognosis 4, 5:

  • Stage 0: Tis, N0, M0
  • Stage I: T1-2, N0, M0 (5-year survival ~93%) 4
  • Stage IIA: T3, N0, M0 (5-year survival ~85%) 4
  • Stage IIB: T4a, N0, M0 (5-year survival ~72%) 4
  • Stage IIC: T4b, N0, M0 4
  • Stage IIIA: T1-2, N1/N1c, M0 or T1, N2a, M0 (5-year survival ~83%) 4
  • Stage IIIB: T3-4a, N1/N1c, M0 or T2-3, N2a, M0 or T1-2, N2b, M0 (5-year survival ~64%) 4
  • Stage IIIC: T4a, N2a, M0 or T3-4a, N2b, M0 or T4b, N1-2, M0 (5-year survival ~44%) 4
  • Stage IV: Any T, Any N, M1 (5-year survival ~8%) 4

Pathological Requirements for Accurate Staging

At least 12 lymph nodes must be examined to accurately stage sigmoid colon cancer and prevent understaging. 2, 4, 5 Fewer than 12 nodes is a recognized quality metric failure that can lead to inappropriate omission of adjuvant chemotherapy in node-negative patients who may actually have occult N1 disease. 4, 5

Additional pathological features that must be documented include 2:

  • Circumferential resection margins (though less critical than in rectal cancer)
  • Vascular invasion (lymphatic and venous)
  • Perineural invasion
  • Tumor deposits (if present)
  • Histologic grade

Key distinction from rectal cancer: Sigmoid colon tumors are defined as those located >15 cm from the anal verge by rigid sigmoidoscopy; tumors ≤15 cm are classified as rectal and staged differently with additional considerations for mesorectal fascia involvement and circumferential resection margin. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

TNM Staging System for Rectal Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Serosal surfaces, mucin pools, and deposits, oh my: challenges in staging colorectal carcinoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015

Guideline

Staging of Colorectal Cancer

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Colorectal Cancer Staging and Treatment Approach

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How do I determine the Tumor‑Node‑Metastasis (TNM) stage for a premenopausal estrogen receptor (ER)-positive breast cancer patient?
What is the recommended staging system and treatment approach for colorectal cancer?
What is the classification of a colorectal tumor that invades through the muscularis propria into the subserosa, specifically a T1 (tumor invading the submucosa), T2 (tumor invading the muscularis propria), T3 (tumor invading through the muscularis propria into the subserosa), or T4 (tumor invading the visceral peritoneum or other organs) lesion?
What is the staging of colon cancer in a patient?
What is the classification of a colorectal tumor that invades through the muscularis propria into the subserosa, specifically in terms of T(n) staging (Tumor staging)?
In a patient with diverticulitis and anemia receiving chemotherapy and immunotherapy who has a low morning cortisol (~1.8 µg/dL) and presents with diarrhea, oral mucositis, gross hematuria and hematochezia, is it appropriate for the oncologist to consider the cortisol level normal, to label these findings as routine side effects, and to forgo ACTH (adrenocorticotropic hormone) stimulation testing, stress‑dose hydrocortisone, and inpatient monitoring?
How should I evaluate and manage bilateral lower-extremity pitting edema?
Should we adjust the medications and plan further management for a 68‑year‑old male with hypertension (on losartan 50 mg daily, an angiotensin II receptor blocker, and amlodipine 5 mg daily, a calcium‑channel blocker), type 2 diabetes mellitus (on glicazide 30 mg daily, a sulfonylurea), coronary artery disease (on trimetazidine 35 mg twice daily, an anti‑ischemic agent), hyperlipidemia (on atorvastatin 10 mg daily, an HMG‑CoA reductase inhibitor), chronic kidney disease stage 3b (creatinine 1.6 mg/dL, impaired renal function), prior stroke, mild anemia (hemoglobin 12.2 g/dL), fasting blood glucose 114 mg/dL (slightly elevated), hemoglobin A1c 7 % (above target), and blood pressure 150/90 mmHg (above target for diabetic patients)?
What is the recommended dosing and duration of dual antiplatelet therapy with aspirin and clopidogrel for an adult patient who recently experienced a transient ischemic attack and has no contraindications to antiplatelet agents?
How can urine osmolality be used to assess dehydration in an adult patient?
How should I manage furosemide‑induced metabolic alkalosis in a patient on a daily dose of 20–80 mg?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.